Amersham gets US approval for Myoview
This article was originally published in Clinica
Executive Summary
Amersham plans to launch its heart imaging agent, Myoview, in the US in March. Recent FDA approval gives Amersham access to the largest market for cardiology imaging. The North American market accounts for £140 million ($213 million) of a £250 million world market. The Tc-99m tetrafosmin kit will be distributed through Medi-Physics, the company's wholly-owned US subsidiary which owns 120 radiopharmacies.
You may also be interested in...
US CDC’s Adult RSV Vaccine Recommendations In Flux With Impending FDA Approvals
Moderna touts enriched Phase II/III population and severe RSV data as CDC advisory committee re-evaluates shared clinical decision-making and prepares for expected June votes on Moderna’s mRNA-1345 and expanded adult use of GSK’s Arexvy.
Roche Nabs FDA Approval For First Of Its Kind Malaria Test
The US FDA has approved Roche’s cobas Malaria test, which screens blood donors in the US for malaria. The cobas is the first such diagnostic to win agency approval.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.